What Is a Peptide? A Plain-Language Primer

Most explanations of this topic are either a biochemistry lecture or a sales page. This one is neither. It is the background I wish I had when I started reading this literature, written for someone who wants to understand the field before spending money in it.

What a peptide actually is

A peptide is a short chain of amino acids joined end to end.

Amino acids are small molecules. Your body uses about twenty of them as building blocks. When two of them link, the bond between them is called a peptide bond, and the result is a peptide. Link more of them and the chain gets longer. That is genuinely the whole definition. Everything else is a question of length and shape.

Length is where the naming gets slippery. The usual convention is that a chain of roughly fifty amino acids or fewer is a peptide, and anything longer is a protein. That line is a convention, not a law of chemistry. Insulin runs to fifty-one amino acids across two chains, which puts it right on the boundary, and you will see it called a peptide hormone in one paper and a small protein in the next. Both are defensible. Nobody is wrong.

What makes peptides interesting is not their size but their job. Many of them are signaling molecules. They carry instructions between cells, bind to receptors, and switch biological processes on or off. Your body produces thousands of them. Insulin tells cells to take up glucose. Oxytocin acts on the uterus and on social behavior. The compounds sold by research peptide vendors are mostly synthetic copies of these signaling molecules, or deliberately modified versions designed to last longer in the body than the natural one does.

One useful consequence of the definition: a lot of things sold alongside peptides are not peptides. MK-677, marketed constantly in peptide circles, is a non-peptide small molecule that happens to act on a related receptor system. I wrote that up separately in the MK-677 research overview. If a vendor cannot tell you what class of molecule they are selling, that tells you something about the vendor.

The discoveries that built the field

Three moments matter more than the rest.

Insulin, 1921 to 1922. At the University of Toronto, Frederick Banting and Charles Best isolated a pancreatic extract that lowered blood glucose in dogs. James Collip purified it enough for human use. In January 1922 a fourteen-year-old named Leonard Thompson became the first person to receive it. He lived another thirteen years. Banting and John Macleod received the Nobel Prize in Physiology or Medicine in 1923, and the credit fight that followed is its own piece of history (Science History Institute; Nobel Prize, Physiology or Medicine 1923). This was the first time a peptide became a medicine, and it reset what was considered possible.

Oxytocin, 1953. Vincent du Vigneaud worked out the amino acid sequence of oxytocin and then built the molecule from scratch in the laboratory. It was the first peptide hormone to have its sequence determined and the first to be synthesized. He received the Nobel Prize in Chemistry in 1955 "for his work on biochemically important sulphur compounds, especially for the first synthesis of a polypeptide hormone" (Nobel Prize, Chemistry 1955). Before this, peptides had to be extracted from tissue. After it, they could be made.

Solid-phase synthesis, 1963 onward. Bruce Merrifield anchored the growing amino acid chain to a solid plastic support so that leftover reagents could simply be washed away after each step. It sounds like a housekeeping improvement. It was not. It turned peptide synthesis from painstaking one-off chemistry into something that could be automated and scaled, and it earned him the Nobel Prize in Chemistry in 1984 "for his development of methodology for chemical synthesis on a solid matrix" (Nobel Prize, Chemistry 1984).

That third one is the reason this market exists. Every vial sold by every vendor I review traces back to Merrifield's method. The chemistry to produce a research peptide is well understood and widely available. That is exactly why the hard question about any given vial is not "can this be made" but "was this one made properly, and can you prove it."

How GLP-1 drugs changed the conversation

For decades peptides were a specialist topic. Then came the GLP-1 class, and the whole field became dinner table conversation.

The origin story is genuinely strange. GLP-1 is a natural gut hormone that prompts insulin release and slows stomach emptying, but the natural version breaks down in the body within minutes, which makes it useless as a medicine. In the early 1990s John Eng, working at a Veterans Affairs hospital in the Bronx, found a closely related peptide in the venom of the Gila monster. That peptide, exendin-4, hit the same receptor and lasted far longer. It became exenatide, marketed as Byetta, approved by the FDA in 2005 as the first GLP-1 receptor agonist (National Institute on Aging; Golden Goose Award).

Everything since has been iteration on that idea. Semaglutide, the prescription pharmaceutical sold as Ozempic, Rybelsus and Wegovy, is a longer-lasting GLP-1 analog with a serious clinical trial record behind its approved indications. Tirzepatide, sold as Mounjaro and Zepbound, hits two receptors instead of one. Retatrutide, still investigational, hits three. I have written each of them up on their own terms: semaglutide, tirzepatide, and retatrutide.

Two things followed from the GLP-1 boom, and they pull in opposite directions.

The first is credibility. GLP-1 drugs demonstrated that a peptide could produce large, measurable, repeatable effects in big randomized trials. That is a real scientific achievement and it lifted interest in the entire class.

The second is a demand problem. Approved GLP-1 products are expensive, require a prescription, and spent a long stretch in shortage. Demand that cannot be met through the front door goes looking for a back one. That is the pressure that built the market this site covers.

The gray market we are actually in

Here is the part most explainers skip.

Compounds like BPC-157, TB-500, ipamorelin and the rest are not approved medicines in the United States. They are also not illegal to sell. They occupy a gap: sold as laboratory research chemicals, labeled for research use only and not for human consumption, shipped in vials with no medical oversight attached to them. The label is not decoration. It is the legal basis on which the entire category is sold.

Two regulatory currents are worth understanding.

Compounding pharmacies got narrower. Compounding is the practice of a licensed pharmacy preparing a medication for a specific patient, governed by sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. During the GLP-1 shortage, compounders were permitted to make copies of semaglutide and tirzepatide. Once the FDA declared those shortages resolved, the tirzepatide shortage in December 2024 and semaglutide in February 2025, that permission wound down on a published timeline, and legal challenges to the decision failed (FDA statement on compounder policies). A route that had been supplying a lot of people closed.

The bulk substance lists moved too, and not in a straight line. The FDA maintains lists of bulk drug substances nominated for use in compounding. Category 2 is the bucket for substances where the agency has identified significant safety risks pending further evaluation. BPC-157 was placed in Category 2 in 2023. As of the FDA's own page last updated April 22, 2026, BPC-157 no longer appears in Category 2 at all. It appears in the section for nominations that were withdrawn (FDA, bulk drug substances that may present significant safety risks).

Read that carefully, because it is easy to misread and vendors will misread it for you. A withdrawn nomination is not an approval. It is not a safety finding in the compound's favor. It means nobody is currently pursuing that substance's addition to the list of things pharmacies may compound with. Some peptides do remain in Category 2, including ipamorelin acetate, GHRP-2 and GHRP-6. "Not currently restricted" and "permitted" are different sentences.

So the honest summary of where we are: the science behind a handful of peptides is strong and getting stronger, the approved products built on that science are expensive and gated, the compounding middle path narrowed sharply, and the research chemical market absorbed the resulting demand while carrying none of the manufacturing oversight that applies to an approved drug. Nothing about a research peptide vial guarantees identity, purity, sterility or accurate labeling. The only evidence you get is whatever documentation the vendor chooses to publish.

That is not a reason to panic. It is a reason to read documents.

Peptides with real regulatory histories

Worth knowing, because it cuts against the assumption that everything in this category is fringe. Several peptides have been through formal approval somewhere.

Sermorelin was sold as the approved prescription drug Geref, then voluntarily withdrawn from the market for commercial reasons rather than safety ones. The full story is in the sermorelin overview.
Tesamorelin is approved for a specific patient population under the brand name Egrifta (tesamorelin overview).
Thymosin alpha-1 is approved in a number of countries as Zadaxin, though not in the United States (thymosin alpha-1 overview).
PT-141, as bremelanotide, is approved as Vyleesi for a narrow indication (PT-141 overview).

And plenty have nothing of the sort. BPC-157 rests almost entirely on rodent studies. Epithalon comes largely from a single research group. Selank and Semax have real clinical trial records that are concentrated in one country's research network. Melanotan II carries published case reports that the dermatology community takes seriously as a warning. The category is not one thing, and treating it as one thing is the most common mistake I see.

What to do with this

If you are researching a specific compound, start with what the literature actually says rather than what a product page says. Every research digest on this site is built to answer that question and to be explicit about where the evidence runs thin.

If you are evaluating where to buy, the documentation is the only leverage you have. A certificate of analysis is the single most informative document a vendor publishes, and most people never open one. I wrote a companion piece on exactly how to read a COA, including the failure patterns that turn up again and again in published certificates. My vendor comparisons apply that standard vendor by vendor, and how I rate vendors lays out the scoring rubric in full.

Nothing on this site is medical advice, and everything discussed here is framed around laboratory research use, which is how these compounds are legally sold. The full disclaimer spells that out.

Sources

Sourcing for research

If you are sourcing any of these compounds for laboratory research, purity documentation matters more than branding. See my vendor comparisons for how I evaluate third-party certificates of analysis.